Product Owner

• Nov 2022 - Present

Healthcare Consultant

• Sep 2021 - Oct 2022

Clinical Researcher

• Apr 2021 - Jun 2021

As a member of this institute, and within the scope of the project, I investigated, in in vitro models of microglia cells (BV2), mechanisms associated with neuroinflammation in the context of exposure of adult animals to methylmercury toxicity. As a member of this institute, and within the scope of the project, I investigated, in in vitro models of microglia cells (BV2), mechanisms associated with neuroinflammation in the context of exposure of adult animals to methylmercury toxicity.

Clinical Researcher

• Jun 2020 - Mar 2021

As a member of the Vectors and Gene Therapy research group, and within the scope of the project, I implemented a combined strategy, involving the manipulation of microRNAs and siRNAs and the lipidome of glioblastoma cells, using Stable Nucleic Acid Lipid Particles (SNALPs), to increase the susceptibility of this cancer to new generation chemotherapeutic agents (e.g., Axitinib) and thus contributing to the eradication of this pathology. As a member of the Vectors and Gene Therapy research group, and within the scope of the project, I implemented a combined strategy, involving the manipulation of microRNAs and siRNAs and the lipidome of glioblastoma cells, using Stable Nucleic Acid Lipid Particles (SNALPs), to increase the susceptibility of this cancer to new generation chemotherapeutic agents (e.g., Axitinib) and thus contributing to the eradication of this pathology.

Researcher MSc Candidate

• Jul 2018 - Oct 2019

For my MSc thesis, I joined the Vectors and Gene Therapy research group, and within the scope of the project, I established and characterized human Pluripotent Stem Cells derived Brain Organoids to model Machado‑Joseph Disease (MJD), concretely, whole‑brain organoids from human induced Pluripotent Stem Cells (hiPSCs), and midbrain/hindbrain organoids from human Neuroepithelial Stem Cells (hNESCs). For my MSc thesis, I joined the Vectors and Gene Therapy research group, and within the scope of the project, I established and characterized human Pluripotent Stem Cells derived Brain Organoids to model Machado‑Joseph Disease (MJD), concretely, whole‑brain organoids from human induced Pluripotent Stem Cells (hiPSCs), and midbrain/hindbrain organoids from human Neuroepithelial Stem Cells (hNESCs).